Rxsight Stock

Rxsight Equity

The The Equity of Rxsight (RXST) as of Aug 7, 2026 is 275.68 M USD. In the previous year, The Equity was 281.24 M USD — a change of -1.98% (lower).

Equity

275.68 MUSD

YoY

-1.98%

Last updated:

In 2026, Rxsight's equity was 275.68 M USD, a -1.98% increase from the 281.24 M USD equity in the previous year.

Access this data via the Eulerpool API

Rxsight Stock analysis

What does Rxsight do? Rxsight Inc is an innovative company that specializes in developing innovative solutions for eye treatments. The company aims to make a positive contribution to the quality of life for patients suffering from eye problems. Rxsight Inc was founded in 2008 by Jim Taylor, who had previously worked in computer graphics at Pixar Animation Studios and was now involved in new technologies for ophthalmology. The business model of Rxsight Inc is based on the development and marketing of medical products that improve the treatment of eye diseases. The company focuses on the field of dynamic ophthalmology, which aims to improve treatment options for eye diseases by focusing on the influence of eye movements and changes in pupil size. Rxsight Inc is divided into various divisions, with an important division focusing on research and development of products that can improve the treatment of eye diseases. The company invests heavily in developing innovative products. Additionally, Rxsight Inc is also involved in the manufacturing and marketing of medical products. Rxsight Inc's products include special contact lenses that can be individually customized through precise measurement of the eye lens. These contact lenses can help patients achieve better visual quality after eye surgery. Rxsight Inc also offers certain measuring devices that are used for measuring and analyzing eye movements and pupil size. Another important product from Rxsight Inc is the "Light Adjustable Lens System," which is a system for intraocular lenses that operates based on feedback from light and energy. The system allows for an individualized process for adjusting the strength of intraocular lenses. With the "Light Adjustable Lens System," patients can achieve significantly improved visual quality after cataract surgery. Overall, Rxsight Inc has established itself as an innovative company in ophthalmology. The company focuses on research and development to provide new technologies for the treatment of eye diseases. Rxsight Inc emphasizes dynamic ophthalmology to consider the influence of eye movements and pupil size in the therapy of eye diseases. With its products, Rxsight Inc makes an important contribution to improving the visual quality of patients. Rxsight is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Rxsight's Equity

Rxsight's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Rxsight's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Rxsight's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Rxsight's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Rxsight’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Rxsight stock

The Equity of Rxsight is 275.68 M USD in 2026.

The Equity of Rxsight changed from 281.24 M USD to 275.68 M USD, representing a -1.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Rxsight since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Rxsight historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Rxsight

All Key Metrics — Rxsight